Tech Company Financing Transactions
Sojournix Funding Round
Sojournix, operating out of Waltham, raised $44 million from Boxer Capital, Frazier Healthcare Partners and Janus Henderson Investors.
Transaction Overview
Company Name
Announced On
1/4/2019
Transaction Type
Venture Equity
Amount
$44,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance SJX-653, a novel, potent, and selective neurokinin-3 (NK3) receptor antagonist in clinical development as a once-daily non-hormonal treatment for menopausal vasomotor symptoms (commonly referred to as hot flashes).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 Totten Pond Rd. 110
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
Sojournix is a clinical stage pharmaceutical company focused on creating new medicines to improve the treatment of women's health and neuroendocrine disorders. We are advancing SJX-653, a novel, potent, selective NK3 antagonist in clinical development as a once-daily non-hormonal therapy for moderate to severe vasomotor symptoms due to menopause.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel Grau
Chief Financial Officer
Karen Roberts
VP - Operations
Jennifer Cormier
VP - Product Management
Philip Graham
VP - Regulatory Affairs
Ann Robbins
Browse more venture capital transactions:
Prev: 1/4/2019: Ostara Nutrient Recovery Technologies venture capital transaction
Next: 1/4/2019: Immusoft venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to document tech company VC transactions. VC transactions reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs